Development of conditions for isolation of antidepressant paroxetine from biological fluids
DOI:
https://doi.org/10.24959/nphj.24.133Keywords:
paroxetine, biological fluids, extraction, UV spectrophotometryAbstract
Aim. To develop optimized conditions for isolating the new antidepressant paroxetine from model blood and urine samples by the liquid extraction followed by the determination of the analyte using the UV spectrophotometric method.
Materials and methods. The studies were performed with model samples of the donor blood and urine spiked with paroxetine. In the sample preparation of blood, the form elements were previously precipitated by 10 % solution of trichloroacetic acid. Endogenous impurities were removed by the extraction purification with chloroform from an acidic medium at pH 1, and paroxetine was extracted from the biological fluids under study with ethyl acetate at pH 10. The organic extracts obtained were further purified using the TLC method. After that, the determination of paroxetine in the eluates obtained from chromatograms was performed using the UV spectrophotometric method.
Results and discussion. The Rf value of paroxetine in the mobile phase of ethyl acetate-methanol-25 % ammonium hydroxide solution (85:15:10) was 0.42 ± 0.02. The UV spectra of eluates from chromatograms had absorption maxima at wavelengths of 265 ± 2, 272 ± 2 and 293 ± 2 nm and matched with the UV spectrum of a standard solution of paroxetine in 0.1 M solution of hydrochloric acid. The quantitative determination was performed at λmax293 nm according to the equation of the calibration curve y=0.0094x–0.02. The methods developed allowed to isolate 70.0 ± 4.0 % of paroxetine from the urine, 26.0 ± 3.0 % from the blood plasma and additionally 5.4 ± 0.6 % of the antidepressant studied from the blood cell sediment after its preliminary separation from the blood plasma.
Conclusions. The optimized conditions for sample preparation of model blood and urine samples by the liquid extraction method in relation to paroxetine have been determined. The results obtained are of applied practical significance for creating an algorithm in the toxicological study of biological fluids for the presence of this antidepressant in fatal drug intoxications.
References
Guaiana, G., Meader, N., Barbui, C., Davies, S. J., Furukawa, T. A., Imai, H. et al. (2023). Pharmacological treatments in panic disorder in adults: a network meta-analysis. Cochrane Database of Systematic Reviews, 11 (11), CD012729. doi: 10.1002/14651858.CD012729.pub3.
Hudd, T. R., Blake, C. S., Rimola-Dejesus, Y., Nguyen, T.-T., Zaiken, K. A. Case Report of Serotonin. (2020). Syndrome in a Patient on Selective Serotonin Reuptake Inhibitor (SSRI) Monotherapy. Journal of Pharmacy Practice, 33 (2), 206-212. doi:10.1177/0897190019841742.
Moffat, A. C., Osselton, M. D., Widdop, B. (2011). Clarke’s analysis of drugs and poisons in pharmaceuticals, body fluids and postmortem material. (4-th ed.). London, Chicago.
Baselt C. R. (2011). Disposition of Toxic Drugs and Chemicals in Man. Seal Beach, California.
Fernández, M. R., Wille, S. M., Samyn, N. (2012). Quantitative method validation for the analysis of 27 antidepressants and metabolites in plasma with ultraperformance liquid chromatography-tandem mass spectrometry. Therapeutic Drug Monitoring, 34 (1), 11-24. doi: 10.1097/FTD.0b013e31823bf0fd.
Eibak, L. E., Gjelstad, A., Rasmussen, K. E., Pedersen-Bjergaard, S. (2012). Exhaustive electromembrane extraction of some basic drugs from human plasma followed by liquid chromatography-mass spectrometry Journal of Pharmaceutical and Biomedical Analysis, 57, 33-38. doi: 10.1016/j.jpba.2011.08.026.
Cai, P., Xiong, X., Li, D., Zhou, Y., Xiong, C. (2020). Magnetic solid-phase extraction coupled with UHPLC-MS/MS for four antidepressants and one metabolite in clinical plasma and urine samples. Bioanalysis, 12 (1), 35-52. doi: 10.4155/bio-2019-0171.
Ma, W., Gao, X., Guo, H., Chen, W. (2021). Determination of 13 antidepressants in blood by UPLC-MS/MS with supported liquid extraction pretreatment. Journal of Chromatography B, Analytical Technologies in the Biomedical Life Sciences, 1171, 122608. doi: 10.1016/j.jchromb.2021.122608.
Amundsen, I., Oiestad, A. M., Ekeberg, D., Kristoffersen, L. (2013). Quantitative determination of fifteen basic pharmaceuticals in ante- and post-mortem whole blood by high pH mobile phase reversed phase ultra high performance liquid chromatography-tandem mass spectrometry. Journal of Chromatography B, Analytical Technologies in the Biomedical Life Sciences, 927 (1), 112-123. doi: 10.1016/j.jchromb.2012.12.039.
Snamina, M., Wietecha-Posłuszny, R., Zawadzki, M. (2019). Postmortem analysis of human bone marrow aspirate – Quantitative determination of SSRI and SNRI drugs. Talanta, 204, 607-612. doi: 10.1016/j.talanta.2019.06.054.
Papoutsis, I., Khraiwesh, A., Nikolaou, P., Pistos, C., Spiliopoulou, C., Athanaselis, S. (2012). A fully validated method for the simultaneous determination of 11 antidepressant drugs in whole blood by gas chromatography–mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 70, 557-562. doi: 10.1016/j.jpba.2012.05.007.
Cabarcos-Fernández, P., Tabernero-Duque, M. J., Álvarez-Freire, I., Bermejo-Barrera, A. M. (2021). Determination of Seven Antidepressants in Pericardial Fluid by Means of Dispersive Liquid-Liquid Microextraction (DLLME) and Gas Chromatography-Mass Spectrometry (GC/MS). Journal of Analytical Toxicology, 46 (1), 146-56. doi: 10.1093/jat/bkab003.
Das, R., Agrawal, Y. K. (2013). Simultaneous Monitoring of Selective Serotonin Reuptake Inhibitors in Human Urine, Plasma and Oral Fluid by Reverse-Phase High Performance Liquid Chromatography. Journal of Chromatographic Science, 51 (2), 146-154. doi: 10.1093/chromsci/bms119.
Jickells, S., Negrusz, A. (Eds.). (2008). Clarke’s Analytical Forensic Toxicology. London.
American Board of Forensic Toxicology “Forensic Toxicology Laboratory Accreditation Checklist”. (2023, July). Available at: https://www.abft.org/wp-content/uploads/2023/04/ABFT_LAP-Checklist_2023-v.Jan-31.pdf.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
